Study Evaluating MYO-029 in Adult Muscular Dystrophy

Wyeth is now a wholly owned subsidiary of Pfizer108 enrolled

Overview

The purpose of this phase I/II, multicenter, safety trial is to study MYO-029 in adult patients with muscular dystrophy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

108

Conditions

Becker Muscular Dystrophy Facioscapulohumeral Muscular Dystrophy Limb-Girdle Muscular Dystrophy

Interventions

MYO-029DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Written informed consent. * Confirmed clinical and molecular diagnosis of Becker Muscular Dystrophy (BMD), Facioscapulohumeral Muscular Dystrophy (FSHD), or Limb-Girdle Muscular Dystrophy (LGMD) * Independently ambulatory Exclusion Criteria: * Patients with certain clinical conditions * Patients using steroids or other medications with the potential to affect muscle function * History of sensitivity to monoclonal antibodies or protein pharmaceuticals * Pregnant or lactating women.

Locations (9)

Unnamed facility

Washington D.C., District of Columbia, United States

Unnamed facility

Kansas City, Kansas, United States

Unnamed facility

Baltimore, Maryland, United States

Unnamed facility

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Safety assessment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.